San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...
Bio advances obesity treatment with IBIO-600, a long-acting anti-myostatin antibody designed for subcutaneous use, targeting ...
In consideration for these rights, iBio has agreed to pay AstralBio an upfront license fee of $750,000, to be paid in shares of iBio’s common stock. Additionally, milestone payments of up to $28 ...
An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long ...
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today ...
The upfront payment of $750,000 in common stock to AstralBio may dilute existing shareholders' equity. iBio is solely responsible for the development and commercialization of IBIO-600, placing ...
(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...
Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio will be eligible for ...
On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio ...
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback